RetinaRisk wins NLS Award for their work with Diabetic Retinopathy risk management
RetinaRisk latest

RetinaRisk wins NLS Invest Rising Star Award

Following a tight battle between 80 candidates, the prestigious NLS Invest has given an award to RetinaRisk, alongside ApoGlyx from Sweden and Respinor from Norway as a “Rising Star” in the Digital/E-Health chapter for startups and selected to pitch to investors at the NLS Days.

As per Nordic Life Sciences News, “The three winners will be awarded a package prize of 15,000 DKK, two registrations to NLSDays 2022, and one company presentation at the 2022 conference.”

NLS Invest Rising Star Awards


This year’s Awards are sponsored by SwedenBIO, the national industry organization for life sciences in Sweden, and BioInnovation Institute (BII) an international commercial foundation with a non-profit objective supported by the Novo Nordisk Foundation.

For the category of Biotech/Pharma: the Swedish ApoGlyx has taken home the award for “developing small molecule inhibitors for Aquaporin-9. Aquaporins have been well recognized as important drug targets. Apoglyx’s most advanced approach targets sepsis, for which there is currently no cure.”

For the Medtech/Diagnostics category, the Norwegian Respinor is currently developing “a novel, non-invasive, ultrasound-based medical device for continuous diaphragm monitoring, with potential applications towards many aspects of critical care and respiratory medicine.”

NLS Invest 2021 Edition placard
Top nordic Startups participating at this yearly event

About RetinaRisk

Our work regarding our clinically validated algorithm that allows for the making of our risk management solution for diabetic retinopathy has been recognized as a novel approach to helping millions of people worldwide get better care and for healthcare institutions to get better tools to deal with the leading preventable cause of blindness due to diabetes. We offer solutions for the B2C market with our APP with close to a million downloads and our API, geared towards hospitals, clinics, diabetes platforms, pharmaceuticals and health insurers in order to streamline eye screening, identify high-risk patients and provide more personalized care.

We are extremely proud and very thankful for this opportunity and we would like to also congratulate the other winners and participants. We also look forward to our presentation in the NLS Days 2022 Digital Edition.

Source: NLS News and SwedenBIO

Similar Posts